These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 5565429)

  • 1. The influence of heart failure, liver disease, and renal failure on the disposition of lidocaine in man.
    Thomson PD; Rowland M; Melmon KL
    Am Heart J; 1971 Sep; 82(3):417-21. PubMed ID: 5565429
    [No Abstract]   [Full Text] [Related]  

  • 2. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans.
    Thomson PD; Melmon KL; Richardson JA; Cohn K; Steinbrunn W; Cudihee R; Rowland M
    Ann Intern Med; 1973 Apr; 78(4):499-508. PubMed ID: 4694036
    [No Abstract]   [Full Text] [Related]  

  • 3. [Present status in and prospects for anti-arrhythmic drug therapy: Drug therapy for arrhythmic patients with heart failure, kidney failure, liver dysfunction or in pregnancy].
    Watanabe E
    Nihon Naika Gakkai Zasshi; 2006 Feb; 95(2):261-70. PubMed ID: 16536076
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacokinetic principles of lidocaine dosing in relation to disease state.
    Waller ES
    J Clin Pharmacol; 1981 Apr; 21(4):181-94. PubMed ID: 7240439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excessive serum lidocaine levels during maintenance infusions: mechanisms and prevention.
    Davison R; Parker M; Atkinson AJ
    Am Heart J; 1982 Aug; 104(2 Pt 1):203-8. PubMed ID: 7102503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of lidocaine on refractory periods in man.
    Josephson ME; Caracta AR; Lau SH; Gallagher JJ; Damato AN
    Am Heart J; 1972 Dec; 84(6):778-86. PubMed ID: 4669900
    [No Abstract]   [Full Text] [Related]  

  • 7. Multiple bolus technique for lidocaine administration in acute ischemic heart disease. II. Treatment of refractory ventricular arrhythmias and the pharmacokinetic significance of severe left ventricular failure.
    Wyman MG; Slaughter RL; Farolino DA; Gore S; Cannom DS; Goldreyer BN; Lalka D
    J Am Coll Cardiol; 1983 Oct; 2(4):764-9. PubMed ID: 6886235
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of propranolol, quinidine, procainamide and lidocaine in chronic renal disease.
    Lowenthal DT
    Am J Med; 1977 Apr; 62(4):532-8. PubMed ID: 851126
    [No Abstract]   [Full Text] [Related]  

  • 9. Clinical pharmacokinetics of digitoxin.
    Perrier D; Mayersohn M; Marcus FI
    Clin Pharmacokinet; 1977; 2(4):292-311. PubMed ID: 902449
    [No Abstract]   [Full Text] [Related]  

  • 10. Lidocaine kinetics predicted by indocyanine green clearance.
    Zito RA; Reid PR
    N Engl J Med; 1978 May; 298(21):1160-3. PubMed ID: 651945
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with antiarrhythmic drugs.
    Goldman P; Ingelfinger JA
    N Engl J Med; 1978 May; 298(21):1193-4. PubMed ID: 651949
    [No Abstract]   [Full Text] [Related]  

  • 12. Does indocyanine green predict lidocaine requirements?
    N Engl J Med; 1978 Sep; 299(12):662-3. PubMed ID: 683244
    [No Abstract]   [Full Text] [Related]  

  • 13. The influence of liver functional ability on blood levels of lidocaine after intraoral submucous application.
    Perovic J; Petrovic V; Obradovic O; Todorovic L
    Bull Group Int Rech Sci Stomatol Odontol; 1979 Apr; 22(2):51-5. PubMed ID: 294300
    [No Abstract]   [Full Text] [Related]  

  • 14. Influence of chronic liver disease and chronic renal failure on nutrient metabolism and undernutrition.
    Cano N; Leverve XM
    Nutrition; 1997 Apr; 13(4):381-3. PubMed ID: 9178296
    [No Abstract]   [Full Text] [Related]  

  • 15. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
    De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
    Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Slower lidocaine elimination and dose adjustment in patients with heart failure].
    Follath F; Ritz R; Vozeh S; Wenk M
    Schweiz Med Wochenschr; 1982 May; 112(22):789-91. PubMed ID: 6808662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lidocaine disposition kinetics in monkey and man. I. Prediction by a perfusion model.
    Benowitz N; Forsyth FP; Melmon KL; Rowland M
    Clin Pharmacol Ther; 1974 Jul; 16(1):87-98. PubMed ID: 4210516
    [No Abstract]   [Full Text] [Related]  

  • 18. [Basic problems of antiarrhythmic treatment (author's transl)].
    Follath F
    Schweiz Rundsch Med Prax; 1981 Sep; 70(37):1583-8. PubMed ID: 7053142
    [No Abstract]   [Full Text] [Related]  

  • 19. Oral lignocaine: its absorption and effectiveness in ventricular arrhythmia control.
    Parkinson PI; Margolin L; Dickson DS
    Br Med J; 1970 Apr; 2(5700):29-30. PubMed ID: 5440571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous infusion of lidocaine in patients with cardiac arrhythmias. Unpredictability of plasma concentrations.
    Sawyer DR; Ludden TM; Crawford MH
    Arch Intern Med; 1981 Jan; 141(1):43-5. PubMed ID: 7447583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.